Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts

British Journal of Dermatology

Volumn 157, Issue 4, 2007, Pages 662-669

  Yasukawa, K ^a   Sawamura, D ^a   Goto, M ^a   Nakamura, H ^a   Shimizu, H ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dermal fibroblast; Gene expression; Histone deacetylase inhibitor; Human keratinocytes; Stratified epidermal sheet

Indexed keywords

FR 901228; HISTONE DEACETYLASE INHIBITOR; PROTEIN; PROTEIN CHAP 31; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; FIBROBLAST; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CELL;

ACETYLATION; CELL DEATH; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; KERATINOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TRANSFECTION; TRANSGENES;

EID: 34548556060     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08122.x     Document Type: Article

References (37)

1. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci U S A 1991 88 : 1330 4.
2. Pfutzner W, Vogel JC. Advances in skin gene therapy. Expert Opin Investig Drugs 2000 9 : 2069 83.
3. Wolffe AP, Pruss D. Targeting chromatin disruption: transcription regulators that acetylate histones. Cell 1996 84 : 817 19.
4. Pikaart MJ, Recillas-Targa F, Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 1998 12 : 2852 62.
5. Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 2004 9 : 135 54.
6. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005 96 : 293 304.
7. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000 92 : 1210 16.
8. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001 13 : 477 83.
9. Stadler WM, Margolin K, Ferber S et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006 5 : 57 60.
10. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003 9 : 3578 88.
11. Okada T, Uchibori R, Iwata-Okada M et al. A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. Mol Ther 2006 13 : 738 46.
12. Taura K, Yamamoto Y, Nakajima A et al. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression. J Gene Med 2004 6 : 526 36.
13. Goldsmith ME, Kitazono M, Fok P et al. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 2003 9 : 5394 401.
14. Kitazono M, Rao VK, Robey R et al. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood 2002 99 : 2248 51.
15. Tobias CA, Kim D, Fischer I. Improved recombinant retroviral titers utilizing trichostatin A. Biotechniques 2000 29 : 884 90.
16. Nan X, Hyndman L, Agbi N et al. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA. Biochem Biophys Res Commun 2004 324 : 348 54.
17. Yamamoto S, Yamano T, Tanaka M et al. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 2003 10 : 179 86.
18. Yamano T, Ura K, Morishita R et al. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 2000 1 : 574 80.
19. Tsuji N, Kobayashi M, Nagashima K et al. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 1976 29 : 1 6.
20. Qiu L, Kelso MJ, Hansen C et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999 80 : 1252 8.
21. Ueda H, Nakajima H, Hori Y et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 1994 47 : 301 10.
22. Nakajima H, Kim YB, Terano H et al. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998 241 : 126 33.
23. Furumai R, Komatsu Y, Nishino N et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci U S A 2001 98 : 87 92.
24. Komatsu Y, Tomizaki KY, Tsukamoto M et al. Cyclic hydroxamic-acid- containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 2001 61 : 4459 66.
25. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002 62 : 4916 21.
26. Boukamp P, Petrussevska RT, Breitkreutz D et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988 106 : 761 71.
27. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975 6 : 331 43.
28. Komatsu Y, Yukutake Y, Yoshida M. Four different clones of mouse anti-acetyllysine monoclonal antibodies having different recognition properties share a common immunoglobulin framework structure. J Immunol Methods 2003 272 : 161 75.
29. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997 90 : 595 606.
30. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998 396 : 594 8.
31. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000 97 : 10014 19.
32. Ogryzko VV, Hirai TH, Russanova VR et al. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol 1996 16 : 5210 18.
33. Munro J, Barr NI, Ireland H et al. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res 2004 295 : 525 38.
34. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998 393 : 386 9.
35. van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996 5 : 245 53.
36. Branski LK, Pereira CT, Herndon DN, Jeschke MG. Gene therapy in wound healing: present status and future directions. Gene Ther 2007 14 : 1 10.
37. Kang WK, Park C, Yoon HL et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001 12 : 671 84.